FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Conditions:   Non Small Cell Lung Cancer;   Colorectal Cancer;   Breast Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Head and Neck Cancer;   GastroEsophageal Cancer
Interventions:   Drug: FT536;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2;   Combination Product: Avelumab;   Combination Product: Pembrolizumab;   Combination Product: Nivolumab;   Combination Product: Atezolizumab;   Combination Product: Trastuzumab;   Combination Product: Cetuximab;   Combination Product: Amivantamab
Sponsor:   Fate Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 28, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments